|
1
|
Ritossa P: Problems of prophylactic
vaccinations of infants. Riv Ist Sieroter Ital. 37:79–108. 1962.(In
Italian).
|
|
2
|
Lindquist S and Craig EA: The heat-shock
proteins. Annu Rev Genet. 22:631–677. 1988. View Article : Google Scholar
|
|
3
|
Georgopoulos C and Welch WJ: Role of the
major heat shock proteins as molecular chaperones. Annu Rev Cell
Biol. 9:601–634. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gething MJ and Sambrook J: Protein folding
in the cell. Nature. 355:33–45. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parsell DA and Lindquist S: The function
of heat-shock proteins in stress tolerance: degradation and
reactivation of damaged proteins. Annu Rev Genet. 27:437–496. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bukau B, Deuerling E, Pfund C and Craig
EA: Getting newly synthesized proteins into shape. Cell.
101:119–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castelli C, Ciupitu AM, Rini F, et al:
Human heat shock protein 70 peptide complexes specifically activate
antimelanoma T cells. Cancer Res. 61:222–227. 2001.PubMed/NCBI
|
|
8
|
Craig EA, Weissman JS and Horwich AL: Heat
shock proteins and molecular chaperones: mediators of protein
conformation and turnover in the cell. Cell. 78:365–372. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z and Srivastava PK: Tumor rejection
antigen gp96/grp94 is an ATPase: implications for protein folding
and antigen presentation. EMBO J. 12:3143–3151. 1993.PubMed/NCBI
|
|
10
|
Sherman M and Multhoff G: Heat shock
proteins in cancer. Ann N Y Acad Sci. 1113:192–201. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milani V, Noessner E, Ghose S, et al: Heat
shock protein 70: role in antigen presentation and immune
stimulation. Int J Hyperthermia. 18:563–575. 2002.PubMed/NCBI
|
|
12
|
Srivastava PK, DeLeo AB and Old LJ: Tumor
rejection antigens of chemically induced sarcomas of inbred mice.
Proc Natl Acad Sci USA. 83:3407–3411. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vanaja DK, Grossmann ME, Celis E and Young
CY: Tumor prevention and antitumor immunity with heat shock protein
70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic
adenocarcinoma of mouse prostate cells. Cancer Res. 60:4714–4718.
2000.PubMed/NCBI
|
|
14
|
Tamura Y, Peng P, Liu K, Daou M and
Srivastava PK: Immunotherapy of tumors with autologous
tumor-derived heat shock protein preparations. Science.
278:117–120. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nicchitta CV: Biochemical, cell biological
and immunological issues surrounding the endoplasmic reticulum
chaperone GRP94/gp96. Curr Opin Immunol. 10:103–109. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Testori A, Richards J, Whitman E, et al:
Phase III comparison of vitespen, an autologous tumor-derived heat
shock protein gp96 peptide complex vaccine, with physician’s choice
of treatment for stage IV melanoma: the C-100-21 Study Group. J
Clin Oncol. 26:955–962. 2008.PubMed/NCBI
|
|
17
|
Wood C, Srivastava P, Bukowski R, et al:
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen)
versus observation alone for patients at high risk of recurrence
after nephrectomy for renal cell carcinoma: a multicentre,
open-label, randomised phase III trial. Lancet. 372:145–154. 2008.
View Article : Google Scholar
|
|
18
|
Shinagawa N, Yamazaki K, Tamura Y, et al:
Immunotherapy with dendritic cells pulsed with tumor-derived gp96
against murine lung cancer is effective through immune response of
CD8+ cytotoxic T lymphocytes and natural killer cells. Cancer
Immunol Immunother. 57:165–174. 2008.PubMed/NCBI
|
|
19
|
Sato K, Torimoto Y, Tamura Y, et al:
Immunotherapy using heat-shock protein preparations of leukemia
cells after syngeneic bone marrow transplantation in mice. Blood.
98:1852–1857. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Srivastava PK: Immunotherapy of human
cancer: lessons from mice. Nat Immunol. 1:363–366. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kojima T, Yamazaki K, Tamura Y, et al:
Granulocyte-macrophage colony-stimulating factor gene-transduced
tumor cells combined with tumor-derived gp96 inhibit tumor growth
in mice. Hum Gene Ther. 14:715–728. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kovalchin JT, Murthy AS, Horattas MC,
Guyton DP and Chandawarkar RY: Determinants of efficacy of
immunotherapy with tumor-derived heat shock protein gp96. Cancer
Immun. 1:72001.PubMed/NCBI
|
|
23
|
Srivastava P: Roles of heat-shock proteins
in innate and adaptive immunity. Nat Rev Immunol. 2:185–194. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmitt E, Gehrmann M, Brunet M, Multhoff
G and Garrido C: Intracellular and extracellular functions of heat
shock proteins: repercussions in cancer therapy. J Leukoc Biol.
81:15–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Srivastava P: Interaction of heat shock
proteins with peptides and antigen presenting cells: chaperoning of
the innate and adaptive immune responses. Annu Rev Immunol.
20:395–425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berwin B and Nicchitta CV: To find the
road traveled to tumor immunity: the trafficking itineraries of
molecular chaperones in antigen-presenting cells. Traffic.
2:690–697. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schild H and Rammensee HG: gp96 - the
immune system’s Swiss army knife. Nat Immunol. 1:100–101. 2000.
|
|
28
|
Castelli C, Rivoltini L, Rini F, et al:
Heat shock proteins: biological functions and clinical application
as personalized vaccines for human cancer. Cancer Immunol
Immunother. 53:227–233. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Srivastava PK and Das MR: The
serologically unique cell surface antigen of Zajdela ascitic
hepatoma is also its tumor-associated transplantation antigen. Int
J Cancer. 33:417–422. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoos A and Levey DL: Vaccination with heat
shock protein-peptide complexes: from basic science to clinical
applications. Expert Rev Vaccines. 2:369–379. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gross L: Intradermal immunization of C3H
mice against a sarcoma that originated in an animal of the same
line. Cancer Res. 323–326. 1943.
|
|
32
|
Klein G, Sjogren HO, Klein E and Hellstrom
KE: Demonstration of resistance against methylcholanthrene-induced
sarcomas in the primary autochthonous host. Cancer Res.
20:1561–1572. 1960.PubMed/NCBI
|
|
33
|
Prehn RT and Main JM: Immunity to
methylcholanthrene-induced sarcomas. J Natl Cancer Inst.
18:769–778. 1957.PubMed/NCBI
|
|
34
|
Old LJBE, Clarke DA and Carswell EA:
Antigenic properties of chemically induced tumors. Ann NY Acad Sci.
80–106. 1962.
|
|
35
|
Ullrich SJ, Robinson EA, Law LW,
Willingham M and Appella E: A mouse tumor-specific transplantation
antigen is a heat shock-related protein. Proc Natl Acad Sci USA.
83:3121–3125. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Srivastava PK, Menoret A, Basu S, Binder
RJ and McQuade KL: Heat shock proteins come of age: primitive
functions acquire new roles in an adaptive world. Immunity.
8:657–665. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Udono H and Srivastava PK: Comparison of
tumor-specific immunogenicities of stress-induced proteins gp96,
hsp90 and hsp70. J Immunol. 152:5398–5403. 1994.PubMed/NCBI
|
|
38
|
Srivastava PK, Chen YT and Old LJ:
5′-structural analysis of genes encoding polymorphic antigens of
chemically induced tumors. Proc Natl Acad Sci USA. 84:3807–3811.
1987.
|
|
39
|
Srivastava PK and Maki RG: Stress-induced
proteins in immune response to cancer. Curr Top Microbiol Immunol.
167:109–123. 1991.PubMed/NCBI
|
|
40
|
Zhu X, Zhao X, Burkholder WF, et al:
Structural analysis of substrate binding by the molecular chaperone
DnaK. Science. 272:1606–1614. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bukau B and Horwich AL: The Hsp70 and
Hsp60 chaperone machines. Cell. 92:351–366. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Udono H and Srivastava PK: Heat shock
protein 70-associated peptides elicit specific cancer immunity. J
Exp Med. 178:1391–1396. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Janetzki S, Palla D, Rosenhauer V, Lochs
H, Lewis JJ and Srivastava PK: Immunization of cancer patients with
autologous cancer-derived heat shock protein gp96 preparations: a
pilot study. Int J Cancer. 88:232–238. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rivoltini L, Castelli C, Carrabba M, et
al: Human tumor-derived heat shock protein 96 mediates in vitro
activation and in vivo expansion of melanoma- and colon
carcinoma-specific T cells. J Immunol. 171:3467–3474. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Z, Qiao Y, Liu B, et al: Combination of
imatinib mesylate with autologous leukocyte-derived heat shock
protein and chronic myelogenous leukemia. Clin Cancer Res.
11:4460–4468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Blachere NE, Li Z, Chandawarkar RY, et al:
Heat shock protein-peptide complexes, reconstituted in vitro,
elicit peptide-specific cytotoxic T lymphocyte response and tumor
immunity. J Exp Med. 186:1315–1322. 1997. View Article : Google Scholar
|
|
47
|
Martin S, Lappin MB, Kohler J, et al:
Peptide immunization indicates that CD8+ T cells are the dominant
effector cells in trinitrophenyl-specific contact hypersensitivity.
J Invest Dermatol. 115:260–266. 2000.
|
|
48
|
Abiru N, Maniatis AK, Yu L, et al: Peptide
and major histocompatibility complex-specific breaking of humoral
tolerance to native insulin with the B9-23 peptide in
diabetes-prone and normal mice. Diabetes. 50:1274–1281. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Srivastava PK, Udono H, Blachere NE and Li
Z: Heat shock proteins transfer peptides during antigen processing
and CTL priming. Immunogenetics. 39:93–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Binder RJ, Han DK and Srivastava PK: CD91:
a receptor for heat shock protein gp96. Nat Immunol. 1:151–155.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Basu S, Binder RJ, Ramalingam T and
Srivastava PK: CD91 is a common receptor for heat shock proteins
gp96, hsp90, hsp70 and calreticulin. Immunity. 14:303–313. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Suto R and Srivastava PK: A mechanism for
the specific immunogenicity of heat shock protein-chaperoned
peptides. Science. 269:1585–1588. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Singh-Jasuja H, Toes RE, Spee P, et al:
Cross-presentation of glycoprotein 96-associated antigens on major
histocompatibility complex class I molecules requires
receptor-mediated endocytosis. J Exp Med. 191:1965–1974. 2000.
View Article : Google Scholar
|
|
54
|
Matsutake T and Srivastava PK: CD91 is
involved in MHC class II presentation of gp96-chaperoned peptides.
Cell Stress Chaperones. 3782000.
|
|
55
|
Basu S, Binder RJ, Suto R, Anderson KM and
Srivastava PK: Necrotic but not apoptotic cell death releases heat
shock proteins, which deliver a partial maturation signal to
dendritic cells and activate the NF-kappa B pathway. Int Immunol.
12:1539–1546. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Moré SH, Breloer M and von Bonin A:
Eukaryotic heat shock proteins as molecular links in innate and
adaptive immune responses: Hsp60-mediated activation of cytotoxic T
cells. Int Immunol. 13:1121–1127. 2001.PubMed/NCBI
|
|
57
|
Lehner T, Bergmeier LA, Wang Y, et al:
Heat shock proteins generate beta-chemokines which function as
innate adjuvants enhancing adaptive immunity. Eur J Immunol.
30:594–603. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Panjwani NN, Popova L and Srivastava PK:
Heat shock proteins gp96 and hsp70 activate the release of nitric
oxide by APCs. J Immunol. 168:2997–3003. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Singh-Jasuja H, Scherer HU, Hilf N, et al:
The heat shock protein gp96 induces maturation of dendritic cells
and down-regulation of its receptor. Eur J Immunol. 30:2211–2215.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Binder RJ, Anderson KM, Basu S and
Srivastava PK: Cutting edge: heat shock protein gp96 induces
maturation and migration of CD11c+ cells in vivo. J Immunol.
165:6029–6035. 2000.PubMed/NCBI
|
|
61
|
Ciupitu AM, Petersson M, Kono K, Charo J
and Kiessling R: Immunization with heat shock protein 70 from
methylcholanthrene-induced sarcomas induces tumor protection
correlating with in vitro T cell responses. Cancer Immunol
Immunother. 51:163–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Baker-LePain JC, Sarzotti M, Fields TA, Li
CY and Nicchitta CV: GRP94 (gp96) and GRP94 N-terminal geldanamycin
binding domain elicit tissue nonrestricted tumor suppression. J Exp
Med. 196:1447–1459. 2002. View Article : Google Scholar
|
|
63
|
Li G, Zeng Y, Chen X, et al: Human ovarian
tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell
responses in vitro. Clin Exp Immunol. 148:136–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pilla L, Patuzzo R, Rivoltini L, et al: A
phase II trial of vaccination with autologous, tumor-derived
heat-shock protein peptide complexes Gp96, in combination with
GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer
Immunol Immunother. 55:958–968. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Murshid A, Gong J and Calderwood SK:
Purification, preparation and use of chaperone-peptide complexes
for tumor immunotherapy. Methods Mol Biol. 960:209–217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gao Y, Chen X, Gao W, Yang Y, Ma H and Ren
X: A new purification method for enhancing the immunogenicity of
heat shock protein 70-peptide complexes. Oncol Rep. 28:1977–1983.
2012.PubMed/NCBI
|
|
67
|
Enomoto Y, Bharti A, Khaleque AA, et al:
Enhanced immunogenicity of heat shock protein 70 peptide complexes
from dendritic cell-tumor fusion cells. J Immunol. 177:5946–5955.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gong J, Zhang Y, Durfee J, et al: A heat
shock protein 70-based vaccine with enhanced immunogenicity for
clinical use. J Immunol. 184:488–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
